CDMRP Neurofibromatosis Exploration-Hypothesis Development Award
ID: 355147Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355147
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Neurofibromatosis Exploration-Hypothesis Development Award to support innovative research in neurofibromatosis (NF) types 1 and 2, as well as schwannomatosis. This grant aims to facilitate high-risk, high-reward studies that can lead to groundbreaking advancements in NF understanding, diagnosis, and treatment, particularly benefiting military personnel and their families. The total funding available for this program is $1,120,000, with up to $100,000 awarded per project over a two-year period, and applications must be submitted in two phases: a pre-application by September 12, 2024, and a full application by October 3, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942524NFRPEHDA_GG.pdf
    The Department of Defense (DOD) is announcing the FY24 Neurofibromatosis Exploration-Hypothesis Development Award as part of the Neurofibromatosis Research Program. This funding aims to support innovative research related to neurofibromatosis (NF) types 1 and 2 and schwannomatosis, ultimately improving diagnosis and treatment. The award offers up to $100,000 over a two-year period, with a total appropriation of $25 million for FY24. Applications must undergo a two-step submission process, including a pre-application due by September 12, 2024, and full applications due by October 3, 2024. Key areas of emphasis include advancements in NF understanding, technological innovation, and health services research pertinent to military personnel and their families. Applicants are encouraged to foster collaboration across disciplines and organizations. Peer review will evaluate the merit based on innovation, research strategy, and potential impact. Compliance with institutional requirements, data sharing, and rigorous study design is mandated. The program seeks to facilitate high-risk, high-reward research that significantly impacts NF research and patient care, demonstrating DOD's commitment to addressing critical health challenges faced by service members and the broader community.
    Similar Opportunities
    NFRP Outreach and Invitation for Response
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), is forecasting an opportunity for a Research-based Other Transactions Agreement (rOTA) under the Neurofibromatosis Research Program (NFRP). This initiative aims to accelerate the clinical translation of basic research related to neurofibromatosis (NF) by conducting collaborative Phase I and II clinical trials focused on promising therapeutic agents for NF1, NF2, and schwannomatosis. Historically, this requirement has been addressed through assistance agreements, and the government is now seeking feedback on this proposed approach, emphasizing the need for cost-sharing arrangements and access to patient populations. Interested parties can direct inquiries to Jason D. Kuhns at jason.d.kuhns.civ@mail.mil, with the opportunity being part of the FY21 portfolio and requiring a demonstrated history of collaborative research among participants.
    DoD Bone Marrow Failure, Investigator-Initiated Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Bone Marrow Failure Research Program (BMFRP) Investigator-Initiated Research Award, aimed at advancing research on bone marrow failure (BMF) diseases. This grant opportunity includes two funding levels: Funding Level 1 (FL1) focuses on developing mature ideas and translating discoveries into clinical applications, while Funding Level 2 (FL2) supports efforts to facilitate Investigational New Drug (IND) applications for promising therapeutic candidates. With a total estimated funding of $2.44 million available for two awards, the program encourages innovative and collaborative research proposals that address critical questions in BMF disease management. Interested applicants must submit a pre-application by July 17, 2024, with the full application due by October 9, 2024; for assistance, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DOD Glioblastoma, Hypothesis Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the Fiscal Year 2024 Glioblastoma Hypothesis Development Award, aimed at funding innovative research to improve glioblastoma patient outcomes. This grant supports exploratory projects that address significant issues in glioblastoma research, particularly in areas such as drug delivery and biomarker identification, without requiring preliminary data. The total estimated funding for this program is approximately $4.64 million, with an expected 13 awards to be made, each with a funding limit of $200,000 for single principal investigators and $300,000 for partnering teams, over a performance period of up to two years. Interested applicants must submit a Letter of Intent by November 6, 2024, followed by a full application by November 20, 2024; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.
    DoD Multiple Sclerosis, Clinical Trial Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Multiple Sclerosis Clinical Trial Award to support clinical trials aimed at improving treatment and management of multiple sclerosis (MS). This funding opportunity encourages innovative trials that may include new pharmacologic agents, devices, or emerging technologies, with a total estimated program funding of $8 million and the expectation of awarding three grants. Eligible applicants include unrestricted entities, and the funding levels are set at a maximum of $2 million for small-scale trials and $4 million for larger-scale studies, with a pre-application deadline of June 10, 2024, and a full application deadline of October 7, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    DoD Bone Marrow Failure, Idea Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the Bone Marrow Failure Research Program (BMFRP) Idea Development Award for FY24, aimed at supporting innovative research to understand and cure bone marrow failure diseases. This grant opportunity encourages both Established Investigators and Early-Career Investigators to propose high-impact research studies with a strong scientific rationale, focusing on conditions such as Aplastic Anemia and Fanconi Anemia, while excluding funding for clinical trial costs. With an estimated total program funding of $4.24 million and the expectation of awarding five grants, interested applicants must submit a pre-application through eBRAP followed by a full application via Grants.gov by the deadline of October 9, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DOD Glioblastoma, Resource Development Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering the Fiscal Year 2024 Glioblastoma Resource Development Award, aimed at enhancing research capabilities for glioblastoma, a malignant brain tumor. This grant supports the development of preclinical model systems that improve the understanding and treatment of glioblastoma, with a focus on innovative approaches such as animal models, organoids, and patient-derived xenografts. With a total funding pool of $4 million, the program anticipates awarding up to five grants, each capped at $500,000 over three years. Interested applicants must submit a pre-application by November 6, 2024, followed by a full application due by November 20, 2024, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Multiple Sclerosis, Investigator-Initiated Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Materiel Command (USAMRAA), is offering a funding opportunity for the Fiscal Year 2024 Multiple Sclerosis Research Program (MSRP) via the Investigator-Initiated Research Award (IIRA). This grant aims to support innovative and high-impact research projects related to Multiple Sclerosis (MS), particularly those that can enhance patient care and quality of life, while excluding clinical trials. The program emphasizes research on central nervous system repair, disease progression correlates, symptom biology, and MS etiology, with a total funding pool of $6 million expected to yield approximately six awards, each up to $1 million over three years. Interested applicants must submit a pre-application by June 10, 2024, followed by a full application due by October 7, 2024, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Multiple Sclerosis, Early Investigator Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Multiple Sclerosis Early Investigator Research Award (MSRP EIRA) to support innovative research focused on multiple sclerosis (MS) by early-stage investigators. This grant aims to foster the development of postdoctoral researchers with less than four years of experience, encouraging them to collaborate with experienced mentors to address critical needs in MS research, particularly in areas such as CNS repair, disease activity correlates, and MS symptomatology. The total funding available for this program is $1.6 million, with an expected five awards, each providing a maximum budget of $320,000 over two years. Key deadlines include a pre-application due by July 24, 2024, and a full application due by October 7, 2024. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
    DoD Arthritis, Focused Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the DoD Arthritis Focused Research Award (Funding Opportunity Number: HT942524ATRPFRA) to support innovative research aimed at improving patient care for individuals affected by arthritis. This grant encourages applications that explore high-risk, high-reward research addressing various types of arthritis, including osteoarthritis and rheumatoid arthritis, with a particular focus on the implications for military personnel and their families. The total funding available for FY24 is approximately $2.5 million, with individual project budgets capped at $750,000 for Research Level 2 and $500,000 for Research Level 1. Interested applicants must submit a pre-application by October 16, 2024, and a full application by October 30, 2024, and can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.
    DoD Combat Readiness - Medical, Translational Research Award
    Active
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Combat Readiness - Medical Translational Research Award (CRRP TRA) to support high-impact translational research aimed at enhancing medical readiness for military personnel. This funding opportunity seeks proposals that address critical areas such as battlefield diagnostics, treatments for life-threatening injuries, and operational health threats, with an emphasis on projects that leverage existing resources and demonstrate clear relevance to military health. The total estimated funding for this initiative is approximately $3.3 million, with the expectation of awarding around three grants, and key deadlines include pre-applications due by September 4, 2024, and full proposals by December 5, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.